Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuezhou Wu

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Pharmacological Research|May 8, 2019
N-Acylethanolamine acid amidase (NAAA) inhibitor F215 as a novel therapeutic agent for osteoarthritisPan Zhou, Lei Xiang, Yulong Yang, et al.
Journal of Nanobiotechnology|July 2, 2026
Cartilage targeted grape skin-derived extracellular vesicles ameliorate osteoarthritis by attenuating chondrocyte senescenceWanzhuo Chen, Luyu Niu, Yuezhou Wu, et al.
Infectious Diseases and Therapy|September 3, 2025
A Comparative Review of the Pharmacology of Dalbavancin and Oritavancin for Gram-Positive Infections: Birds of a Feather or Apples and Oranges?Maytham Hussein, James Barclay, Mark Baker, et al.
Antimicrobial Agents and Chemotherapy|November 18, 2025
Prolonged exposure to teixobactin generates cross-tolerance to other cell wall-targeting antimicrobials in <i>Enterococcus faecalis</i>Rachel L Darnell, Melanie K Knottenbelt, Olivia E Rose, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Pharmacological Research|May 8, 2019
N-Acylethanolamine acid amidase (NAAA) inhibitor F215 as a novel therapeutic agent for osteoarthritisPan Zhou, Lei Xiang, Yulong Yang, et al.
Journal of Nanobiotechnology|July 2, 2026
Cartilage targeted grape skin-derived extracellular vesicles ameliorate osteoarthritis by attenuating chondrocyte senescenceWanzhuo Chen, Luyu Niu, Yuezhou Wu, et al.
Infectious Diseases and Therapy|September 3, 2025
A Comparative Review of the Pharmacology of Dalbavancin and Oritavancin for Gram-Positive Infections: Birds of a Feather or Apples and Oranges?Maytham Hussein, James Barclay, Mark Baker, et al.
Antimicrobial Agents and Chemotherapy|November 18, 2025
Prolonged exposure to teixobactin generates cross-tolerance to other cell wall-targeting antimicrobials in <i>Enterococcus faecalis</i>Rachel L Darnell, Melanie K Knottenbelt, Olivia E Rose, et al.
Pageof 3